NASDAQ:RGLS
Regulus Therapeutics Inc. Stock News
$2.00
+0 (+0%)
At Close: May 17, 2024
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer
08:00am, Thursday, 16'th May 2024
SAN DIEGO , May 16, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the
Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates
04:05pm, Thursday, 09'th May 2024
Initiated the fourth cohort of patients in the Phase 1b multiple-ascending dose (MAD) clinical trial of RGLS8429 for the treatment of autosomal dominant polycystic kidney disease (ADPKD) Topline data
The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028
06:00am, Tuesday, 07'th May 2024
Finding good investment opportunities in the constantly changing stock market is similar to uncovering hidden treasures. Certain cheap stocks to buy are particularly noteworthy because they can yield
SAN DIEGO , May 6, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the
Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series
08:00am, Tuesday, 30'th Apr 2024
SAN DIEGO , April 30, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (
Regulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKD
12:51pm, Wednesday, 10'th Apr 2024
Regulus Therapeutics Inc. achieved positive results in cohort 2 of phase 1b study, using RGLS8429 for patients with autosomal polycystic kidney disease; Improvement of PC1 & PC2 proteins and reduction
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
04:05pm, Thursday, 21'st Mar 2024
Positive topline data from the second cohort of patients in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study
01:11pm, Wednesday, 13'th Mar 2024
Data from an early-stage study shows that treatment with Regulus' (RGLS) lead drug shows increased biological activity at a higher dose in patients with autosomal dominant polycystic kidney disease.
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
06:32am, Tuesday, 12'th Mar 2024
SAN DIEGO , March 12, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (t
Mechanistic dose response observed at a 2mg/kg dose level based on urinary biomarker analyses Encouraging exploratory results of imaging-based biomarkers with greatest reductions in total kidney volum
SAN DIEGO , Jan. 2, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (t
Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
08:00am, Wednesday, 22'nd Nov 2023
SAN DIEGO , Nov. 22, 2023 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (
SAN DIEGO , Oct. 19, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (t
Statistically significant increase in urinary polycystin 1(PC1) after treatment with RGLS8429 Urinary polycystin exhibits anticipated pharmacokinetics/pharmacodynamics (PK/PD) correlation in patients
SAN DIEGO , Sept. 13, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (
